1-(4-乙氧基苯基)哌嗪 | 46415-29-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-(4-乙氧基苯基)哌嗪
• 中文别名: 5-甲氧基异酞酸
• 英文名称: 4-(4-ethoxyphenyl)piperazine
• 英文别名: 1-(4-ethoxy-phenyl)-piperazine；1-(4-Ethoxyphenyl)piperazine
• CAS: 46415-29-6
• 化学式: C₁₂H₁₈N₂O
• mdl: MFCD00191209
• 分子量: 206.288
• InChiKey: DPEWTQJUUDLJNX-UHFFFAOYSA-N

物化性质

• 沸点：
  120 °C
• 密度：
  1.040±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  24.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  2-氯-1-[4-(7-氯喹啉-4-基)哌嗪-1-基]乙酮 、 1-(4-乙氧基苯基)哌嗪 在 sodium carbonate 作用下， 以 乙醇 为溶剂， 反应 12.0h， 以68%的产率得到1-(4-(7-chloroquinolin-4-yl)piperazin-1-yl)-2-(4-(4-ethoxyphenyl)piperazin-1-yl)ethanone
  参考文献：
  名称：

  某些 7-Chloro-4-(piperazin-1-yl)quinoline 衍生物作为 VEGFR-II 抑制剂的设计、合成和细胞毒性评估

  摘要：

  VEGFR-II 的信号通路抑制被视为癌症管理中的宝贵工具。在目前的研究中，新型 1-4-(7-氯喹啉-4-基)哌嗪-1-基)-2-(N-取代氨基)-乙酮衍生物 (4a-t) 的合成是通过2-氯-1-(4-(7-氯喹啉-4-基)哌嗪-1-基)乙酮(3)与不同仲胺的胺化。目标化合物的结构经IR、1H-NMR、13C-NMR、HRMS和微量分析确证。对化合物 4a-t 进行了针对人乳腺癌 (MCF-7) 和前列腺癌 (PC3) 细胞系的体外抗癌筛选。2-(4-(4-bromobenzyl)piperazin-1-yl)-1-(4-(7-chloroquinolin-4-yl)piperazin-1-yl)ethanone (4q )，对 MCF-7 和 PC3 细胞的 IC50 值分别为 6.502 和 11.751 μM，与标准药物阿霉素相比（MCF-7：6.774 μM，PC3：7.7316

  DOI：

  10.1002/ardp.201600377
• 作为产物：
  描述：

  哌嗪 、 4-溴苯乙醚 生成 1-(4-乙氧基苯基)哌嗪
  参考文献：
  名称：

  Potent, selective, and orally active adenosine A2A receptor antagonists: Arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines

  摘要：

  Antagonism of the adenosine A2A receptor offers great promise in the treatment of Parkinson's disease. Employing the known pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine A2A antagonist SCH 58261 as a starting point, we identified the potent and selective (vs. A1) antagonist 11h, orally active in the rat haloperidol-induced catalepsy model. We further optimized this lead to the methoxyethoxyethyl ether 12a (SCH 420814), which shows broad selectivity, good pharmacokinetic properties, and excellent in vivo activity.

  DOI：

  10.1016/j.bmcl.2006.11.083

文献信息

• [EN] QUINOLONE CARBOXYLIC ACID DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE CONDITIONS<br/>[FR] DERIVES D'ACIDE CARBOXYLIQUE DE QUINOLONE POUR LE TRAITEMENT DES TROUBLES HYPERPROLIFERATIFS
  申请人：BAYER PHARMACEUTICALS CORP

  公开号：WO2005097752A1

  公开（公告）日：2005-10-20

  Quinolone carboxylic acid derivatives of formula (I) wherein Ar is an optionally substituted phenyl, pyridyl, or pyrimidinyl group and the substituent groups R1, R4, R10, R11, R19, and R20 are as defined in the specification, pharmaceutical compositions containing them, and methods of using them in treatment of hyperproliferative diseases such as cancer are disclosed and claimed.

  公开和声明了式(I)的喹诺酮羧酸衍生物，其中Ar是可选择地取代的苯基、吡啶基或嘧啶基，取代基R1、R4、R10、R11、R19和R20如规范中定义，包含它们的药物组合物，以及在治疗癌症等高增殖性疾病中使用它们的方法。
• PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS
  申请人：Han Bo

  公开号：US20080306086A1

  公开（公告）日：2008-12-11

  The present invention relates to a compound of formula I wherein R 2 R 3 , R 4 , R 5 , X, n, and o are as defined herein and to a pharmaceutically acceptable acid addition salt thereof which are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

  本发明涉及一种具有如下式I的化合物 其中 R 2 R 3 ，R 4 ，R 5 ， X，n和o如本文所定义，并且其药学上可接受的酸盐，它们是治疗抑郁症、疼痛、精神病、帕金森病、精神分裂症、焦虑和注意力缺陷多动障碍（ADHD）的高潜力NK-3受体拮抗剂。
• NOVEL CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND
  申请人：Kwak Byong Sung

  公开号：US20110195963A1

  公开（公告）日：2011-08-11

  There is provided a novel carbamoyloxy arylalkanoyl arylpiperazine derivative compound having abundant racemic or enantiomeric characteristics, represented by the Formula 1, and pharmaceutically available salts or hydrates thereof. Also, there are provided a pharmaceutical composition for treating pain, anxiety or depression including an effective amount of the compound, and a method for treating pain, anxiety or depression in mammals by administering an effective amount of the compound to the mammals in need of treatment thereof.

  提供一种新颖的卡巴莫氧基芳基丙酰基芳基哌嗪衍生物化合物，具有丰富的外消旋或对映体特征，其化学式如下所示，并且提供其药用盐或水合物。此外，还提供了一种用于治疗疼痛、焦虑或抑郁的药物组合物，包括一定量的该化合物，并且提供了一种治疗哺乳动物疼痛、焦虑或抑郁的方法，通过向需要治疗的哺乳动物施用一定量的该化合物。
• Pyrrolo-pyridine derivatives
  申请人：Merck Sharpe & Dohme Ltd.

  公开号：US05432177A1

  公开（公告）日：1995-07-11

  A class of pyrrolo[2,3-b]pyridine derivatives, substituted at the 3-position by a substituted piperazinylmethyl moiety, are antagonists of dopamine receptor subtypes within the brain, having a selective affinity for the dopamine D.sub.4 receptor subtype over other dopamine receptor subtypes, and are accordingly of benefit in the treatment and/or prevention of psychotic disorders such as schizophrenia while manifesting fewer side-effects than those associated with classical neuroleptic drugs.

  一类吡咯并[2,3-b]吡啶衍生物，其在3位被取代的哌嗪甲基基团是大脑内多巴胺受体亚型的拮抗剂，具有对多巴胺D.sub.4受体亚型的选择性亲和力，相比经典的神经阻滞药物，对治疗和/或预防精神分裂症等精神障碍有益，并表现出较少的副作用。
• ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR
  申请人：Nippon Chemiphar Co., Ltd.

  公开号：EP1897872A1

  公开（公告）日：2008-03-12

  A compound having the following formula or its salt is used as an activator for PPAR: [in which W2 represents a bond, C(C=O) or CH2; Z2 represents an oxygen or sulfur atom; R21, R22 and R23 independently represent a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, an alkoxy group having 1 to 8 carbon atoms, a halogen atom, an alkyl group having 1 to 8 carbon atoms which is substituted with a halogen atom or the like; and R24 and R25 independently represent a hydrogen atom, an alkyl group having 1 to 8 carbon atoms or an alkyl group having 1 to 8 carbon atoms which is substituted with a halogen atom].

  具有以下化学式或其盐的化合物被用作PPAR的激活剂：[其中W2代表键，C(C=O)或CH2；Z2代表氧原子或硫原子；R21、R22和R23分别代表氢原子，具有1至8个碳原子的烷基基团，具有1至8个碳原子的烷氧基团，卤素原子，具有1至8个碳原子的烷基基团，该基团被卤素原子或类似物取代；R24和R25分别代表氢原子，具有1至8个碳原子的烷基基团或具有1至8个碳原子的烷基基团，该基团被卤素原子取代]。